| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 16 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 31% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $361,700, and 10 were calls, valued at $382,255.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $26.5 for Pfizer over the last 3 months.
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $13.0 to $26.5 in the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | PUT | TRADE | BEARISH | 11/21/25 | $0.64 | $0.56 | $0.63 | $24.00 | $189.0K | 31.2K | 3.6K |
| PFE | CALL | TRADE | NEUTRAL | 12/17/27 | $14.0 | $9.0 | $11.47 | $13.00 | $63.0K | 603 | 50 |
| PFE | CALL | TRADE | NEUTRAL | 12/17/27 | $14.0 | $9.0 | $11.5 | $13.00 | $57.5K | 603 | 0 |
| PFE | CALL | TRADE | BULLISH | 11/21/25 | $0.29 | $0.26 | $0.28 | $25.50 | $56.0K | 7.1K | 165 |
| PFE | PUT | SWEEP | BULLISH | 11/14/25 | $2.35 | $1.96 | $1.96 | $26.00 | $52.1K | 499 | 267 |
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
1 market experts have recently issued ratings for this stock, with a consensus target price of $32.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Morgan Stanley persists with their Equal-Weight rating on Pfizer, maintaining a target price of $32.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.
Posted In: PFE
